Literature DB >> 29119236

Imaging the multiple facets of immuno-oncology.

Chaitanya Divgi1.   

Abstract

Mesh：

Year:  2018        PMID： 29119236     DOI： 10.1007/s00259-017-3869-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  14 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 2.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

3.  Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.

Authors:  Sandra Heskamp; Willemijn Hobo; Janneke D M Molkenboer-Kuenen; Daniel Olive; Wim J G Oyen; Harry Dolstra; Otto C Boerman
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

4.  89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.

Authors:  Christopher G England; Dawei Jiang; Emily B Ehlerding; Brian T Rekoske; Paul A Ellison; Reinier Hernandez; Todd E Barnhart; Douglas G McNeel; Peng Huang; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-19       Impact factor: 9.236

Review 5.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

6.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Authors:  Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo
Journal:  Cancer Discov       Date:  2016-06-14       Impact factor: 39.397

7.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.

Authors:  Benjamin M Larimer; Eric Wehrenberg-Klee; Frank Dubois; Anila Mehta; Taylor Kalomeris; Keith Flaherty; Genevieve Boland; Umar Mahmood
Journal:  Cancer Res       Date:  2017-05-01       Impact factor: 12.701

8.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

9.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

10.  Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.

Authors:  David J Donnelly; R Adam Smith; Paul Morin; Daša Lipovšek; Jochem Gokemeijer; Daniel Cohen; Virginie Lafont; Tritin Tran; Erin L Cole; Martin Wright; Joonyoung Kim; Adrienne Pena; Daniel Kukral; Douglas D Dischino; Patrick Chow; Jinping Gan; Olufemi Adelakun; Xi-Tao Wang; Kai Cao; David Leung; Samuel J Bonacorsi; Wendy Hayes
Journal:  J Nucl Med       Date:  2017-10-12       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.